Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection

Sophie Marbaix(Pfizer (Belgium)), Derek Weycker(Policy Analysis (United States)), Mark Atwood(Policy Analysis (United States)), Willy Peetermans(KU Leuven), Reiko Sato(Keio University), Jan Verhaegen(KU Leuven), A. Mignon(Pfizer (Belgium)), Lieven Annemans(Ghent University Hospital)
PLoS ONE
July 6, 2018
10.1371/journal.pone.0199427
Cited by 13

Related Papers

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k
3D-printing techniques in a medical setting: a systematic literature review
|BioMedical Engineering OnLine|2016|1.1k
Risk factors for community-acquired pneumonia in adults in Europe: a literature review
|Thorax|2013|861
Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study
|Clinical Infectious Diseases|2005|593